Noxopharm Ltd., of Sydney, said is seeking to raise A$6 million (US$4.4 million) in an IPO and to list on the ASX. In its offering 30 million shares will be sold at $0.20 each under a prospectus, which will remains open until July 18 unless closed earlier. The company’s first anti-cancer drug candidate, NOX66, is poised to enter a phase I study later this year. It is a new dosage form of the drug candidate, idronoxil.